A
Anthony W. Kim
Researcher at University of Southern California
Publications - 257
Citations - 6975
Anthony W. Kim is an academic researcher from University of Southern California. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 39, co-authored 229 publications receiving 5431 citations. Previous affiliations of Anthony W. Kim include Loma Linda University & Cornell University.
Papers
More filters
Journal ArticleDOI
The Eighth Edition Lung Cancer Stage Classification
TL;DR: This paper summarizes the eighth edition of lung cancer stage classification, which is the worldwide standard as of January 1, 2017, based on a large global database, a sophisticated analysis, extensive internal validation as well as multiple assessments confirming generalizability.
Journal ArticleDOI
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
TL;DR: A careful preoperative physiologic assessment is useful for identifying those patients at increased risk with standard lung cancer resection and for enabling an informed decision by the patient about the appropriate therapeutic approach to treating his or her lung cancer.
Journal ArticleDOI
Treatment of Stage III Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Nithya Ramnath,Thomas J. Dilling,Loren J. Harris,Anthony W. Kim,Gaetane Michaud,Alex Balekian,Rebecca L. Diekemper,Frank C. Detterbeck,Douglas A. Arenberg +8 more
TL;DR: Multimodality therapy is preferable in most subsets of patients with stage III lung cancer, and routine platinum-based adjuvant chemotherapy following complete resection of stage IIIA lung cancer encountered unexpectedly at surgery is supported.
Journal ArticleDOI
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn
Stuart Jon Spechler,John G. Hunter,Karen M. Jones,Robert H. Lee,Brian R Smith,Hiroshi Mashimo,Vivian M. Sanchez,Kerry B. Dunbar,Thai H. Pham,Uma K Murthy,Taewan Kim,Christian S. Jackson,Jason Wallen,Erik C von Rosenvinge,Jonathan Pearl,Loren Laine,Anthony W. Kim,Andrew M Kaz,Roger P Tatum,Ziad F Gellad,Sandhya Lagoo-Deenadayalan,Joel H Rubenstein,Amir A. Ghaferi,Wai-Kit Lo,Ronald S. Fernando,Ronald S. Fernando,Bobby S. Chan,Shirley C Paski,Dawn Provenzale,Donald O. Castell,David Lieberman,Rhonda F. Souza,William D. Chey,Stuart Warren,Anne Davis-Karim,Shelby D. Melton,Robert M. Genta,Tracey Serpi,Kousick Biswas,Grant D. Huang +39 more
TL;DR: Systematic workup revealed truly PPI-refractory and reflux-related heartburn in a minority of patients, and surgery was superior to medical treatment for that highly selected subgroup.
Journal ArticleDOI
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Michelle C. Salazar,Joshua E. Rosen,Zuoheng Wang,Brian N. Arnold,Daniel C. Thomas,Roy S. Herbst,Anthony W. Kim,Frank C. Detterbeck,Justin D. Blasberg,Daniel J. Boffa +9 more
TL;DR: In the National Cancer Database, adjuvant chemotherapy remained efficacious when started 7 to 18 weeks after non–small-cell lung cancer resection, and patients who recover slowly from non-small- cell lung cancer surgery may still benefit from delayed adjuant chemotherapy started up to 4 months after surgery.